Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a ...
FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...
Recent research paper titled "Impact of Persistent Pulmonary Hypertension of the Newborn in Neonates with ...
An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.
F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...
A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...
Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help ...
Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...
Frespaciguat is under clinical development by Merck and currently in Phase III for Idiopathic Pulmonary Hypertension. According to GlobalData, Phase III drugs for Idiopathic Pulmonary Hypertension ...
Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 58% phase transition ...